Michael Chao

Papers

Total Citations

H-Index

About

Michael Chao is a leading clinical researcher in radiation oncology, with a primary focus on advancing prostate cancer treatment. His key research areas include brachytherapy, stereotactic ablative body radiotherapy (SABR), and the optimization of treatment-related toxicities and quality of life for patients. Chao’s major contribution lies in demonstrating that modern radiotherapy options—such as brachytherapy and SABR—offer comparable efficacy to surgery while significantly reducing side effects and improving patient convenience. His seminal work, "Brachytherapy: state‐of‐the‐art radiotherapy in prostate cancer" (2015), has garnered 28 citations and remains a cornerstone reference for clinicians weighing treatment trade-offs. Beyond this, his research has shaped clinical guidelines by emphasizing the importance of cost, treatment time, and patient-reported outcomes in decision-making. Chao’s impact is evident in his sustained influence on urologic oncology, where his studies help patients and doctors navigate the complex landscape of prostate cancer care with evidence-based, patient-centered insights.